Initiale Therapie des Status epilepticus

Möddel, Gabriel; Kellinghaus, Christoph; Strzelczyk, Adam

doi:10.1007/s10309-018-0204-z

Cited by 5 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, LZP has sedative-hypnotic and anti-anxiety effects. Common doses for the treatment of SE in adults are 2-4 mg in the pre-hospital phase [37]. The American Epilepsy Society recommends a LZP dose of 0.1 mg/kg (a maximum single dose of 4 mg), which may be repeated [38].…”

Section: Lorazepammentioning

confidence: 99%

Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability

et al. 2022

Self Cite

View full text Add to dashboard Cite

Status epilepticus (SE) is an acute, life-threatening medical condition that requires immediate, effective therapy. Therefore, the acute care of prolonged seizures and SE is a constant challenge for healthcare professionals, in both the pre-hospital and the in-hospital settings. Benzodiazepines (BZDs) are the first-line treatment for SE worldwide due to their efficacy, tolerability, and rapid onset of action. Although all BZDs act as allosteric modulators at the inhibitory gamma-aminobutyric acid (GABA) A receptor, the individual agents have different efficacy profiles and pharmacokinetic and pharmacodynamic properties, some of which differ significantly. The conventional BZDs clonazepam, diazepam, lorazepam and midazolam differ mainly in their durations of action and available routes of administration. In addition to the common intravenous, intramuscular and rectal administrations that have long been established in the acute treatment of SE, other administration routes for BZDs-such as intranasal administration-have been developed in recent years, with some preparations already commercially available. Most recently, the intrapulmonary administration of BZDs via an inhaler has been investigated. This narrative review provides an overview of the current knowledge on the efficacy and tolerability of different BZDs, with a focus on different routes of administration and therapeutic specificities for different patient groups, and offers an outlook on potential future drug developments for the treatment of prolonged seizures and SE.

show abstract

Section: Lorazepammentioning

confidence: 99%

Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Passenderweise zu der Veröffentlichung der deutschsprachigen neuen Klassifikations-und Diagnosekriterien für epileptische Anfälle und Epilepsien werden in dem ersten Beitrag des Themenheftes die neuen Diagnose-und Klassifikationskriterien des Status epilepticus ausführlich und praxisnah erörtert [5,6]. Neueste Erkenntnisse zur stufenadaptierten Therapie des Status epilepticus werden in vier aufeinander abgestimmten Artikeln besprochen [7][8][9][10].…”

Section: Neue Klassifikations-und Diagnosekriterien Für Epileptische unclassified

Neue Klassifikations- und Diagnosekriterien für epileptische Anfälle und Epilepsien

Schmitt

Strzelczyk

2018

Z. Epileptol.

View full text Add to dashboard Cite

“…In der Prähospitalphase gibt es deutliche Schwierigkeiten, einen SE zu erkennen [7,8]. In der Übersicht von G. Möddel et al wird neben den Diagnosekriterien ausführlich die initiale Therapie des SE besprochen, insbesondere unter Berücksichtigung neuer Applikationsformen von Benzodiazepinen, die sicherlich bald auch Eingang in die Leitlinien finden werden [9].…”

unclassified